Funding will support continued development of Calpurbatug (TRL1068), a novel therapy being evaluated for prosthetic joint infections (PJI)

资金将支持Calpurbatug（TRL1068）的持续开发，这是一种正在评估中的新型疗法，用于治疗假体关节感染（PJI）。

REDWOOD CITY, Calif.

加利福尼亚州红木城

,

，

July 16, 2026

2026年7月16日

/PRNewswire/ -- Trellis Bioscience, a clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases, today announced the closing of a $9 million Series C financing. This funding will support completion of the Company's Phase 2 trial of calpurbatug (TRL1068), an investigational mAb treatment for chronic prosthetic joint infections (PJI)..

/美通社/ -- 临床阶段生物技术公司Trellis Bioscience致力于开发天然人源单克隆抗体（mAbs）以治疗难治性感染性疾病，该公司今日宣布完成900万美元的C轮融资。这笔资金将用于支持完成其候选单克隆抗体疗法calpurbatug（TRL1068）的二期临床试验，该疗法旨在治疗慢性假体关节感染（PJI）。

The Series C received continued support from existing investors, including New Science Ventures and Easton Capital, while attracting new investors AMR Action Fund (AMRAF), The Doctor Group of Dallas, Texas, and orthopedic surgeons with extensive expertise in PJI from centers of excellence across the United States.

C轮融资获得了现有投资者（包括New Science Ventures和Easton Capital）的持续支持，同时吸引了新投资者AMR Action Fund（AMRAF）、来自德克萨斯州达拉斯的The Doctor Group，以及来自美国各地卓越中心、在假体周围感染（PJI）领域拥有丰富专业知识的骨科医生。

This brings Trellis's total equity funding to approximately $35 million, matched by a similar amount of non-dilutive grant support from NIAID (National Institute of Allergy and Infectious Disease) and CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, a global nonprofit partnership).

这使得Trellis的股权融资总额达到约3,500万美元，同时获得了来自美国国家过敏和传染病研究所（NIAID）以及CARB-X（对抗抗生素耐药细菌生物制药加速器，一个全球非营利合作伙伴关系）的同等数额的非稀释性赠款支持。

In conjunction with AMRAF's investment, Junjun Gao, PhD, Principal, has been appointed to the Trellis Board of Directors, bringing valuable sector expertise to the company's leadership.

随着AMRAF的投资，高军军博士（Principal）被任命为Trellis公司董事会成员，为公司领导层带来了宝贵的行业专业知识。

'We're excited to have the backing of AMRAF, the most prominent investor in the antimicrobial space, as we move ahead in our efforts to redefine how antibiotic-resistant infections are treated in the future,' said Trellis CEO Geoff Dillon. 'By disrupting bacterial biofilm, calpurbatug represents a new class of agents with potential utility in a substantial number of antibiotic-resistant infections.'.

“在我们推进重新定义未来抗生素耐药性感染治疗方式的努力之际，我们很高兴获得抗微生物领域最知名投资者AMRAF的支持，”Trellis首席执行官Geoff Dillon表示。“通过破坏细菌生物膜，calpurbatug代表了一类新型药剂，可能在大量抗生素耐药性感染中具有潜在应用价值。”

A New Therapeutic Category for Antibiotic-Resistant Infections From—and Beyond—Orthopedic Surgery

用于骨科手术及其他领域耐药性感染治疗的新疗法类别

Prosthetic joint infections are a debilitating, hard-to-treat and costly consequence of knee or hip joint replacements, affecting more than 25,000 patients — or roughly 1-2 percent of joint replacement recipients — annually in the U.S. alone. There are no approved therapeutic treatments for this condition and the current standard of care is a two-stage surgical revision that is associated with significantly diminished quality of life, high failure and five-year mortality rates, and billions of dollars in additional health care expenditures, with estimates indicating that managing PJIs can exceed $400,000 per patient.  A less invasive approach for managing PJIs know as DAIR (debridement, antibiotics, and implant retention) is more patient-friendly but has a substantially higher failure rate, particularly for chronic PJI..

假体关节感染是膝关节或髋关节置换术后一种致残性强、难以治疗且代价高昂的并发症，仅在美国，每年就有超过25,000名患者（约占关节置换受者的1-2%）受到影响。目前尚无针对该病症的获批疗法，当前的标准治疗方式是两阶段手术翻修，这与患者生活质量显著下降、高失败率和高五年死亡率相关，并导致数十亿美元的额外医疗支出；据估计，每位患者的假体关节感染管理费用可超过40万美元。一种被称为DAIR（清创、抗生素保留植入物）的微创治疗方法对患者更为友好，但其失败率明显更高，尤其是在慢性假体关节感染病例中。

The Trellis approach is to attack the antibiotics-resistance associated with PJI at its source. Extensive pre-clinical data and encouraging clinical results to date indicate that calpurbatug (TRL1068) effectively disassembles the biofilm that prevents antibiotics from eliminating the bacterial infection.

Trellis 的方法是从源头上解决与假体周围感染（PJI）相关的抗生素耐药性问题。广泛的临床前数据和迄今为止令人鼓舞的临床结果表明，calpurbatug（TRL1068）能够有效瓦解阻止抗生素清除细菌感染的生物膜。

Jason Adams of The Doctor Group said, 'The emerging results from clinical trials for augmenting the DAIR procedure with TRL1068 suggest that this innovative drug will yield outcomes superior to two-stage revision in a range of bacterial infections. That would be a true game changer in the field — better results and less grueling for the patient.'.

The Doctor Group的Jason Adams表示：“在DAIR手术中联合使用TRL1068的临床试验初步结果显示，这种创新药物在多种细菌感染中的疗效优于两期翻修术。这将是该领域真正的颠覆性突破——不仅疗效更佳，而且对患者的折磨也更少。”

A Growing Healthcare Crisis

日益严重的医疗危机

'The PJI treatment challenge and financial burden are expanding as more joint replacement surgeries are expected for the aging U.S. population,' said John Friedman, Chairman of Easton Capital.

“随着美国人口老龄化，预计关节置换手术量将增加，假体周围感染（PJI）的治疗挑战和财务负担也在不断加重。”伊斯顿资本董事长约翰·弗里德曼表示。

'Infection is a risk with any surgical procedure, and prosthetic joint infections can be devastating for patients,' said Henry Skinner, PhD, CEO of AMR Action Fund. 'The growing threat of antimicrobial resistance is making these infections increasingly difficult to treat. We are pleased to support the Trellis team as they work to develop a therapy that could improve outcomes for patients and help preserve the antibiotic safety net that underpins modern surgical care.'.

“任何手术都存在感染风险，而假体关节感染对患者而言可能是毁灭性的，”AMR行动基金首席执行官亨利·斯金纳博士表示。“抗菌药物耐药性威胁日益加剧，使得这些感染越来越难以治疗。我们很高兴支持Trellis团队，他们正致力于开发一种疗法，有望改善患者预后，并帮助维护支撑现代外科治疗的抗生素安全网。”

Development Status

开发状态

Trellis conducted its first-in-human trial of calpurbatug in PJI patients under an FDA-cleared IND application. In addition to safety and pharmacokinetics data, this Phase 1 trial provided early clinical evidence of biofilm-disrupting activity. The current Phase 2 trial testing TRL1068 in PJI patients as part of a DAIR procedure is fully enrolled, with top line results expected in Q2 2027..

Trellis 在美国食品药品监督管理局（FDA）批准的临床试验申请（IND）下，对假体周围感染（PJI）患者开展了 calpurbatug 的首次人体试验。除安全性和药代动力学数据外，这项 I 期试验还提供了生物膜破坏活性的早期临床证据。目前，作为清创、抗生素灌洗和植入物保留（DAIR）手术的一部分，在 PJI 患者中测试 TRL1068 的 II 期试验已完成全部入组，预计将于 2027 年第二季度公布主要结果。

TRL1068 has received Orphan Drug, Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA, which may help facilitate development and regulatory review and, in the case of QIDP designation, provide additional market exclusivity following approval.

TRL1068已获得美国食品药品监督管理局（FDA）授予的孤儿药、快速通道以及合格传染病产品（QIDP）认定，这些认定可能有助于促进药物开发和监管审评，并且在QIDP认定的情况下，可在获批后提供额外的市场独占期。

About Trellis Bioscience, Inc.

关于Trellis Bioscience公司

Trellis developed a proprietary technology for cloning antibodies, including calpurbatug (TRL1068), from human white blood cells. Human antibodies have a lower failure rate due to toxicity than any other drug class. Applied to infectious diseases, the technology has allowed discovery of antibodies from patients who have recovered from the disease.  In addition to the lead biofilm disruption program, Trellis's pipeline includes antiviral antibodies (one of which is in a clinical trial) targeting major unmet medical needs..

Trellis 开发了一项专有技术，用于从人类白细胞中克隆抗体，包括 calpurbatug（TRL1068）。与其他任何药物类别相比，人源抗体因毒性导致的失败率更低。将该技术应用于传染病领域，使得从已康复患者体内发现抗体成为可能。除了领先的生物膜破坏项目外，Trellis 的产品管线还包括针对重大未满足医疗需求的抗病毒抗体（其中一种正处于临床试验阶段）。

About the Investor Syndicate

关于投资者联盟

Trellis's platform technology development was funded by top-tier venture capital firms and its product development is being funded by AMR Action Fund, The Doctor Group and Key Opinion Leaders (KOLs) as well as by prior institutional investors New Science Ventures and Easton Capital.

Trellis的平台技术开发由顶级风险投资公司资助，其产品开发则由AMR行动基金、医生集团和关键意见领袖（KOL）以及先前的机构投资者新科学风投和伊斯顿资本共同资助。

Media Contact:

媒体联系人：

Nora Mende, CFO

诺拉·门德，首席财务官

[email protected]

[email protected]

SOURCE Trellis Bioscience Inc.

来源：Trellis Bioscience Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示